The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting.
Therefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.
Aged within 18 and 80 years;
Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;
ICP monitoring started for clinical indication and accordingly to local policies
ICP device connected to the Integra CereLink ICP monitor.
ICP monitoring not inserted
No availability of the Integra CereLink ICP monitor.
Patients with an acute brain injury (ABI) due to hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury.
Cohort
Prospective
intracranial pressure monitoring
Procedure/SurgeryInvasive monitoring of intracranial pressure by using CereLink monitor.
Association between PTD and in-hospital mortality.
To assess the association between PTD and in-hospital mortality.
Association between PTD and 6 months GOSE
To assess the association between PTD and 6 months GOSE (Glasgow Outcome Scale extended).
PTD summary measure.
To identify the PTD summary measure (e.g. mmHg/h max, mmHg/day, mmHg/week) that maximize the outcome prediction.
Outcome predictiveness of PTD and end hour ICP.
To compare the outcome predictiveness of PTD and end hour ICP.
Click on the lead sponsor to view all of their trials.
University of Milano Bicocca
Lead sponsor
Integra LifeSciences Corporation
Collaborator
